急性毒性反应在利妥昔单抗联合化疗治疗恶性淋巴瘤中的护理  

Nursing of acute toxicity reactions of Rituximab combined with chemotherapy in the treatment of malignant lymphoma

作　　者：陈秀华[1] 唐美玲[1] 陆平[1] 

机构地区：[1]江苏省南通市第一人民医院血液肿瘤科,江苏南通226001

出　　处：《实用临床医药杂志》2014年第2期23-25,共3页Journal of Clinical Medicine in Practice

摘　　要：目的观察恶性淋巴瘤患者应用利妥昔单抗联合化疗治疗出现的急性毒性反应并探讨相关护理措施。方法回顾性分析20例应用利妥昔单抗联合化疗的恶性淋巴瘤患者的临床资料,观察治疗期间出现的急性毒性反应。结果本组20例患者治疗期间主要毒性反应为变态反应35%、胃肠道反应65%、骨髓抑制80%,心血管反应15%,所有患者均顺利完成靶向药物及化疗治疗。结论利妥昔单抗联合化疗的急性毒性反应发生率较高,护士的密切观察、严格的用药管理、及时有效的护理措施是保证治疗安全的重要基础。Objective To observe acute toxicity reactions of Rituximab combined with chemotherapy in the treatment of malignant lymphoma and to discusses related nursing measures.Methods The clinical materials of 20 patients with malignant lymphoma treated with rituximab and chemotherapy were analyzed. And acute toxic reactions were observed during the treatment.Results The main toxic reactions of the 20 patients were allergic reaction, gastrointestinal reaction, bone marrow inhibition and cardiovascular responses, the percentage were 35%, 65%, 80%and 15% respectively. In the research, all the patients successfully completed targeted drug application and chemotherapy treatment. Conclusion The incidence of acute toxicity reaction of Rituximab combined with chemotherapy in the treatment of malignant lymphoma is high. Thus,close observation, strict management of medication administration and effective nursing in time are important foundation to ensure the safety of treatment.

关 键 词：恶性淋巴瘤 利妥昔单抗 抗肿瘤联合化疗 急性毒性反应 护理 

分 类 号：R473.73[医药卫生—护理学]